Press release
Autoimmune Encephalitis Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight
Discover Key Insights into the Autoimmune Encephalitis Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market [https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Autoimmune Encephalitis Market Report
* On January 14, 2026- Biogen announced a study are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) in Part 1 and to evaluate the effects of BIIB091 combination therapy with DRF compared with the DRF monotherapy arm on the key MRI measure of active central nervous system (CNS) inflammation in Part 2.
* On January 09, 2026- Hoffmann-La Roche announced a phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis.
* Approximately 80% of patients with anti-NMDAR encephalitis are female.
* Children were more prone to movement disorders, while memory deficits and central hypoventilation were more prevalent in adults.
* Autoimmune encephalitis (AIE) primarily affects individuals aged from early teenage years to around 50, with a median onset age of 21 years.
* Around 92% underwent first-line immunotherapy, with approximately 27% receiving second-line immunotherapy.
* The leading Autoimmune Encephalitis Companies such as Hoffmann-La Roche, Takeda Pharmaceutical , and others.
* Promising Autoimmune Encephalitis Therapies such as Satralizumab, GLOVENIN-I (TAK-961) , and others
Stay ahead in the Autoimmune Encephalitis Therapeutics Market with DelveInsight's Strategic Report @ Autoimmune Encephalitis Market Outlook [https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Autoimmune Encephalitis Epidemiology Segmentation in the 7MM
* Autoimmune Encephalitis Prevalent cases
* Autoimmune Encephalitis Type- specific cases
* Autoimmune Encephalitis Age-specific cases
* Autoimmune Encephalitis Gender-specific cases
* Autoimmune Encephalitis Line-wise treated cases
Download the report to understand which factors are driving Autoimmune Encephalitis Epidemiology trends @ Autoimmune Encephalitis Prevalence [https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Emerging Autoimmune Encephalitis Therapies
* Satralizumab: Hoffmann-La Roche
Satralizumab targets B cells, which are involved in the production of autoantibodies. It is used to reduce inflammation and mitigate the immune response in autoimmune encephalitis. Satralizumab is administered subcutaneously, which allows for a more targeted and controlled delivery. Satralizumab is currently being investigated in Phase III (NCT05503264) study, aimed at evaluating its efficacy and safety in patients with anti-NMDAR or anti-LGI1 encephalitis.
* GLOVENIN-I (TAK-961): Takeda Pharmaceutical
TAK-961 (NCT05177939), also known as GLOVENIN-I, is an IVIG product developed by Nihon Pharmaceutical (a subsidiary of Takeda Pharmaceutical Company), currently in Phase III trials for autoimmune encephalitis in Japan. It has multiple therapeutic classifications and mechanisms of action, including amyloid beta-protein inhibition and immunostimulation. It holds orphan drug designations for Stevens-Johnson syndrome and toxic epidermal necrolysis. It is currently marketed in Japan for various conditions, including agammaglobulinemia, bullous pemphigoid, chronic inflammatory demyelinating polyradiculoneuropathy, Guillain-Barre syndrome, motor neuron disease, pemphigus, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
To know more about Autoimmune Encephalitis treatment guidelines, visit @ Autoimmune Encephalitis Treatment Market Landscape [https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Autoimmune Encephalitis Therapies and Companies
* Green Cross Corporation: Immunoglobulin G
* Hoffmann-La Roche: Satralizumab
* Biogen: BIIB091/DRF
* Evergreen Therapeutics Inc.: EG-501
Autoimmune Encephalitis Market Dynamics
The market is expected to grow, fueled by intensified R&D efforts, increased investments from both public and private sectors, and the pressing need for more effective therapies. First-line treatment typically consists of high-dose corticosteroids combined with IVIG or plasmapheresis. Major pharmaceutical players, including Takeda and Hoffmann-La Roche, are actively progressing their pipeline candidates through different stages of clinical development, targeting treatments for Autoimmune Encephalitis. Current management strategies generally involve immunomodulatory therapies, antibody removal procedures, anticonvulsants, antipsychotics, mood stabilizers, and supportive interventions such as physical, occupational, and speech therapy.
Scope of the Autoimmune Encephalitis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Autoimmune Encephalitis Companies- Hoffmann-La Roche, Takeda Pharmaceutical , and others.
- Autoimmune Encephalitis Therapies- Satralizumab, GLOVENIN-I (TAK-961) , and others
- Autoimmune Encephalitis Unmet Needs, KOLs' views, Analysts' views, Autoimmune Encephalitis Market Access and Reimbursement
Learn more about the FDA-approved drugs for Autoimmune Encephalitis @ Drugs for Autoimmune Encephalitis Treatment [https://www.delveinsight.com/sample-request/autoimmune-encephalitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Key Insights
2. Report Introduction
3. Autoimmune Encephalitis Market Overview at a Glance
4. Autoimmune Encephalitis Epidemiology and Market Methodology
5. Autoimmune Encephalitis Executive Summary
6. Key Events
7. Autoimmune Encephalitis Disease Background and Overview
8. Autoimmune Encephalitis Epidemiology and Patient Population
9. Autoimmune Encephalitis Patient Journey
10. Autoimmune Encephalitis Marketed Products
11. Autoimmune Encephalitis Emerging Treatment and Management
12. Autoimmune Encephalitis: 7 Major Market Analysis
13. Autoimmune Encephalitis SWOT Analysis
14. Autoimmune Encephalitis KOL Views
15. Autoimmune Encephalitis Unmet Needs
16. Autoimmune Encephalitis Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autoimmune-encephalitis-market-size-in-the-7mm-is-expected-to-grow-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/autoimmune-encephalitis-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Autoimmune Encephalitis Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight here
News-ID: 4351917 • Views: …
More Releases from ABNewswire
How to Ensure Ventilation for Fire Pumps - Industry Trends and Best Practices
During critical moments of urban safety crises, Fire Pump [https://www.seadpump.com/fire-pump/]s serve as the core line of defense for protecting lives. In sudden fire emergencies, SEAD wear-resistant fire pumps achieve maximum reliability in extreme scenarios through in-depth innovations in mechanical structure, becoming an indispensable robust guarantee in dangerous situations. This guarantee relies not only on the equipment itself but also on scientific supporting design and layout-ventilation and basic layout are precisely…
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust Wi …
DelveInsight's, "Antisense Oligonucleotide Therapeutics Pipeline Insights 2026" report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Antisense Oligonucleotide Therapeutics pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover…
Harm of Cyanobacteria in Water - Industry Trends and Best Practices
Cyanobacteria, also known as blue-green algae, are among the most primitive types of algae. They are unicellular prokaryotes that possess both algal and fungal characteristics. Cyanobacteria thrive in water bodies rich in organic matter and with a relatively high pH value, and they favor high temperatures. They can reproduce in large quantities when the water pH ranges from 8 to 9.5 and the temperature is between 28 degrees C and…
Herpes Zoster Market Size in the 7MM is projected to increase at a significantly …
DelveInsight's "Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Discover Key Insights into the Herpes Zoster Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/herpes-zoster-market [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Herpes Zoster Market Report
*
On January 07, 2026- Pfizer…
More Releases for Autoimmune
Autoimmune Polyglandular Syndrome Market analysis reveals CAGR of 6.20 percent t …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Autoimmune Polyglandular Syndrome Type 1 Market - (By Diagnosis (Serum Autoimmune Screen, End-organ Function Tests, Blood Tests, Others), Age of Onset (Childhood, Adult, Adolescent), Treatment (Medication, Hormone Replacement Therapy, Others), Dosage Form (Tablet, Capsule, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)),…
Reshaping Autoimmune Therapy Landscape: Protheragen Announces Small Molecule Dru …
Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune diseases.
New York, USA - Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune conditions. From target identification to preclinical studies, Protheragen leverages its expertise in small molecule drug design and development to offer tailored services that provide biotech and pharmaceutical companies…
Autoimmune Disease Diagnosis Market - Strength in Knowledge, Defying Autoimmune …
Newark, New Castle, USA: The "Autoimmune Disease Diagnosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Autoimmune Disease Diagnosis Market: https://www.growthplusreports.com/report/autoimmune-disease-diagnosis-market/7616
This latest report researches the industry structure,…
Autoimmune Drugs Market: Understanding How They Work and Their Importance in Tre …
Allied Market Research recently said Autoimmune diseases are a group of disorders in which the body's immune system attacks its own healthy tissues, mistaking them for foreign invaders. These diseases can affect any part of the body, including the joints, skin, and organs. They can be debilitating, chronic, and sometimes life-threatening. Autoimmune drugs are medications that help to suppress or modulate the immune system's response to prevent it from attacking…
Autoimmune Disease Diagnostics Market: Growing Awareness among People about Auto …
According to the recent report by Transparency Market Research, the global autoimmune disease diagnostics market has a highly consolidated scenario. The market is dominated by a handful of players. However, these players have a stronghold over the dynamics of market and pose a great challenge for any new entrant to set its foot in the market.
Read Report Overview - https://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html
To reduce effects of such hindrances, the new entrants are…
Autoimmune Disease Therapeutics Market Boost due to increase in incidence of aut …
According to a new report published by Allied Market Research, titled,"Autoimmune Disease Therapeutics Market by Drug Class, Indication, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is expected to reach $153,320 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185?utm_source=openpr&utm_medium=Niranjan
Autoimmune disease therapeutics include…
